Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'

Bi N.; Liang J.; Wang L.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'

【24h】

Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'

机译：反应对紫杉醇/卡铂的依托磷脂/顺铂的存活优势在III阶段III NSCLC患者中的同时校长：ECOG 2患者的亚组分析将是极大的兴趣

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2017年第12期|共4页
作者
Bi N.; Liang J.; Wang L.;
展开▼
作者单位

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Radiat Oncol Beijing Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest' [J] . Bi N., Liang J., Wang L. Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第12期

机译：反应对紫杉醇/卡铂的依托磷脂/顺铂的存活优势在III阶段III NSCLC患者中的同时校长：ECOG 2患者的亚组分析将是极大的兴趣
2. 9104 Randomized phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group (WJTOG) 0105 [J] . N.Katakami, M.Satouchi, N.Yamamoto, European Journal of Cancer Supplements . 2009,第2期

机译：9104丝裂霉素/长春地辛/顺铂（MVP）与每周伊立替康/卡铂（IC）或每周紫杉醇/卡铂（PC）联合胸腔放疗（CTR）的不可切除的III期非小细胞患者的3期随机研究肺癌（NSCLC）：西日本胸腔肿瘤小组（WJTOG）0105
3. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer [J] . WangL., WuS., OuG., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第1期

机译：Ⅲ期非小细胞肺癌患者同时进行顺铂/依托泊苷或紫杉醇/卡铂联合胸腔放疗的II期随机研究
4. Does Sex Make a Difference in Survival of Patients Undergoing Resection for Early Stage Non-Small Cell Lung Cancer (NSCLC)? [C] . Steven J.Jubelirer, Nicole L.Varela, Christine A.Welch, 21st international conference on screening for lung cancer . 2009

机译：性别对早期非小细胞肺癌（NSCLC）切除患者的生存率有影响吗？
5. The effectiveness of chemoradiation for stage III non-small-cell lung cancer patients at the Kingston Regional Cancer Center (Ontario). [D] . Sinclair, Suzanne Marie. 2003

机译：金斯敦地区癌症中心（安大略省）对III期非小细胞肺癌患者进行化学放射治疗的有效性。
6. Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data [O] . Rafael Santana-Davila, Kiran Devisetty, Aniko Szabo, -1

机译：顺铂和依托泊苷与卡铂和紫杉醇联合放疗治疗Ⅲ期非小细胞肺癌：退伍军人卫生管理数据分析
7. B5-01: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 [O] . Nasser Hanna, Marcus Neubauer, Ronald McGarry, 2007

机译：B5-01：顺铂（P）加胸苷（e）加上同时胸部辐射（XRT）的相III试验，在患者（PTS）中，具有或不具有可行的III阶段非小细胞肺癌（NSCLC）：Hog LUN 01-24 / USO-023

Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'

著录项

相似文献

相关主题

期刊订阅